123 related articles for article (PubMed ID: 31177178)
21. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
22. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
23. Association of ERCC1 Polymorphisms with the Risk of Colorectal Cancer: A Meta-Analysis.
Chen J; Sun N; Hu G; Chen X; Jiang J; Wu H; Luo G
Crit Rev Eukaryot Gene Expr; 2017; 27(3):267-275. PubMed ID: 29199611
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
26. Assoication of XRCC1 gene polymorphisms with risk of non-small cell lung cancer.
Kang S; Ma Y; Liu C; Cao C; Hanbateer ; Qi J; Li J; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4171-6. PubMed ID: 26097609
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China.
Deng Q; Sheng L; Su D; Zhang L; Liu P; Lu K; Ma S
Med Oncol; 2011 Sep; 28(3):667-72. PubMed ID: 20354815
[TBL] [Abstract][Full Text] [Related]
28. Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis.
Zhang L; Wang J; Xu L; Zhou J; Guan X; Jiang F; Wu Y; Fan W
Mutagenesis; 2012 Jan; 27(1):67-76. PubMed ID: 22002622
[TBL] [Abstract][Full Text] [Related]
29. A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer.
Zhang Y; Zhang Z; Cao L; Lin J; Yang Z; Zhang X
Oncotarget; 2017 Jan; 8(4):6216-6221. PubMed ID: 28008159
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
31. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery.
Lee SY; Hong MJ; Jeon HS; Choi YY; Choi JE; Kang HG; Jung DK; Jin C; Do SK; Yoo SS; Seok Y; Lee EB; Shin KM; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Park JY
Oncotarget; 2015 Sep; 6(27):24522-32. PubMed ID: 26056042
[TBL] [Abstract][Full Text] [Related]
32. The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.
Chen LH; Shen TC; Li CH; Chiu KL; Hsiau YC; Wang YC; Gong CL; Wang ZH; Chang WS; Tsai CW; Hsia TC; Bau DT
Cancer Genomics Proteomics; 2020; 17(5):571-577. PubMed ID: 32859635
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
Hamilton G; Rath B
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
[TBL] [Abstract][Full Text] [Related]
34. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
35. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Zhao F; Shang Y; Zeng C; Gao D; Li K
Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
[TBL] [Abstract][Full Text] [Related]
36. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer.
Kim IS; Lee GW; Kim DC; Kim HG; Kim S; Oh SY; Kim SH; Kwon HC
J Thorac Oncol; 2010 Dec; 5(12):1912-21. PubMed ID: 20978448
[TBL] [Abstract][Full Text] [Related]
38. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
39. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.
Zhang ZY; Tian X; Wu R; Liang Y; Jin XY
Asian Pac J Cancer Prev; 2012; 13(6):2583-6. PubMed ID: 22938424
[TBL] [Abstract][Full Text] [Related]
40. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
